MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
2.710
-0.060
-2.17%
Opening 10:14 09/10 EDT
OPEN
2.770
PREV CLOSE
2.770
HIGH
2.770
LOW
2.690
VOLUME
482.13K
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
1.660
MARKET CAP
416.20M
P/E (TTM)
-3.6400
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Dow Jones · 1d ago
Editas Medicine Names Dan Ory Chief Medical Officer
NASDAQ · 2d ago
Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Dow Jones · 2d ago
Weekly Report: what happened at EDIT last week (0831-0904)?
Weekly Report · 3d ago
Editas: Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor
Seeking Alpha · 09/02 19:34
Editas Medicine files $400M mixed securities shelf
TipRanks · 08/31 20:30
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Benzinga · 08/31 20:28
Weekly Report: what happened at EDIT last week (0824-0828)?
Weekly Report · 08/31 09:08
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.